UNIVERSITY HEALTH NETWORK - TED MARRAS, MD
This research program focuses on advancing the understanding, diagnosis, and treatment of nontuberculous mycobacterial (NTM) lung disease through population-based research, clinical trials, and multidisciplinary clinical care aimed at improving outcomes for patients with chronic pulmonary infections.
Ted Marras, MD
Primary Investigator
University Health Network (UHN)
Institution
NTM Lung Disease Clinical Research
Research Focus
Project Overview
The Toronto Western Hospital / University Health Network Nontuberculous Mycobacterial Disease Program is a multidisciplinary academic center within the Division of Respirology. The program integrates physician-investigators, research coordinators, and administrative staff to deliver specialized clinical care while conducting clinical, observational, and interventional research in NTM lung disease.
Project Summary
The program conducts population-based studies using Ontario provincial health data, clinic-based observational studies, and multicenter clinical trials. Research focuses on epidemiology, treatment outcomes, disease progression, and evaluation of new therapeutic strategies for nontuberculous mycobacterial lung disease.
Project Goals
- Improve understanding of NTM epidemiology and outcomes
- Advance treatment strategies through clinical trials
- Support population-based health data research
Impact
The UHN NTM Disease Program contributes to global advancement in the management of nontuberculous mycobacterial lung disease by integrating population health research, clinical trials, and multidisciplinary care to improve diagnosis, treatment, and long-term patient outcomes.
Advancing Research. Improving Lives.
Population-based research and clinical trials advancing outcomes for patients with NTM lung disease.
Ted Marras, MD
Director, Toronto Western Hospital NTM Disease Program
University Health Network (UHN)
ted.marras@uhn.ca
Project Overview
The UHN NTM Disease Program is a multidisciplinary clinical and research center focused on nontuberculous mycobacterial lung disease, integrating population-based studies, clinical trials, and observational research to improve patient care and outcomes.